ACRES Commercial Realty Corp., a real estate investment trust (REIT), focuses on the origination, holding, and management of commercial real estate mortgage loans and equity investments in commercial real estate property in the United States. The company invests in commercial real estate credit investments, including floating-rate first mortgage loans, first priority interests in first mortgage loans, subordinated interests in first mortgage loans, mezzanine financing, preferred equity investments, and CRE equity investments. It qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was formerly known as Exantas Capital Corp. and changed its name to ACRES Commercial Realty Corp. in February 2021. ACRES Commercial Realty Corp. was incorporated in 2005 and is based in Uniondale, New York.

ACRES Commercial Realty Corp.

In a report released on December 12, Julien Richer from Kepler Capital maintained a Hold rating on Accor SA, with a price target of €48.00. The com...

Kepler Capital  Remains a Hold on Accor SA (0H59)

An update from Acrux ( ($AU:ACR) ) is now available. Acrux Limited has divested its Prilocaine 2.5% and Lidocaine 2.5% Cream registration and distr...

Acrux Divests US Rights for Prilocaine and Lidocaine Cream

The latest update is out from KWG Resources ( ($TSE:CACR) ). The Canadian Chrome Company Inc. has announced the terms for a private placement to ra...

Canadian Chrome Company Sets Terms for $25 Million Private Placement

KWG Resources ( ($TSE:CACR) ) has issued an announcement. The Canadian Chrome Company Inc. has expressed satisfaction with recent governmental and ...

Canadian Chrome Company Eyes Strategic Growth in Ring of Fire

The latest update is out from Acrux ( ($AU:ACR) ). Acrux Ltd has announced a change in the director’s interest, with Director John Warmbrunn acquir...

Acrux Director Acquires Significant Unlisted Options

Acrux ( ($AU:ACR) ) has shared an update. Acrux Limited has announced a change in the interests of its director, Geoffrey Brooke, involving the acq...

Acrux Director’s Interest Update: Significant Rights Acquisition

Acrux ( ($AU:ACR) ) just unveiled an update. Acrux Ltd announced a change in the director’s interest, with Tim Oldham acquiring 2,866,719 unlisted ...

Acrux Director Acquires Unlisted Rights, Aligning Interests with Company Goals

Acrux ( ($AU:ACR) ) just unveiled an update. Acrux Ltd has announced a change in the director’s interest, specifically involving Don Brumley. The c...

Acrux Ltd Announces Director’s Interest Change

Acrux ( ($AU:ACR) ) has provided an announcement. Acrux Limited has announced a change in the interests of its director, Ross Dobinson, with the ac...

Acrux Director Acquires Additional Unlisted Rights

Acrux ( ($AU:ACR) ) has provided an announcement. Acrux Limited announced the results of its Annual General Meeting held on November 25, 2025, wher...

Acrux Limited Announces Successful AGM Resolutions

The latest announcement is out from Acrux ( ($AU:ACR) ). Acrux Ltd’s recent announcement at their Annual General Meeting highlights the company’s s...

Acrux Ltd Navigates Market Challenges with Strategic Focus

An announcement from Acrux ( ($AU:ACR) ) is now available. Acrux Ltd, a company listed on the ASX, has announced a change in the director’s interes...

Acrux Ltd Director Increases Shareholding

The latest announcement is out from Acrux ( ($AU:ACR) ). Acrux Limited has announced the quotation of 1,345,002 ordinary fully paid securities on t...

Acrux Limited Announces Quotation of New Securities on ASX

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Intellia Therapeutics (NTLA – Research Report) and...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Intellia Therapeutics (NTLA) and Acrivon Therapeutics, Inc. (ACRV)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Acrivon Therapeutics, Inc. (ACRV – Research Report...

Analysts Conflicted on These Healthcare Names: Acrivon Therapeutics, Inc. (ACRV) and Bristol-Myers Squibb (BMY)

In a report released today, Donald Fandetti from Wells Fargo maintained a Sell rating on Ares Commercial, with a price target of $4.00. According t...

Wells Fargo Keeps Their Sell Rating on Ares Commercial (ACRE)

KWG Resources ( ($TSE:CACR) ) has shared an announcement. The Canadian Chrome Company Inc. has observed heightened trading activity in its shares b...

Market Cap	$160.21M	P/E Ratio	NaN
52W High	$24.17	52W Low	$14.94
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	N/A	52W Position	95.0%
Overall Score	71	Value Score	80
Quality Score	63	Technical Score	72

EPS Current Est	$NA	EPS Next Est	$NA
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ACR	$23.71	+0.04%	36.99K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ACR	$23.71	+0.0%	36.99K
3
4
5
6

ACR

ACR

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get ACRES Commercial Realty Corp. Data in Excel

Get ACRES Commercial Realty Corp. Data in Excel